ADDENDUM This ADDENDUM (this " Addendum ") dated January 12 th , 2017 (the " Effective Date ") to the Collaborative Agreement dated

ADDENDUM (this "Addendum") dated January 12th , 2017 (the "Effective Date")

to the Collaborative Agreement dated December 29, 2015 (as amended hereby, the "Agreement") by and between BioLite,

Inc., a company incorporated under the laws of Taiwan and having its principal place of business at 3rd Floor, 248, Nei-Hu Road,

Sec. l , Taipei, 11493 Taiwan ("BioLite") and American BriVision Corporation, a Delaware corporation having its

principle place of business at 11, Sawyer Park Drive, Goshen, New York 10294 USA ("ABVC"). BioLite and

ABVC are thereafter referred to as the "Parties".

the Parties desire to amend the Agreement;

THEREFORE, the Parties, in consideration of the mutual promises herein contained and for other good and valuable consideration,

the receipt and sufficiency of which is hereby acknowledged, hereby agree to amend the Agreement as follows:

1.1 The Agreement is hereby amended to add the following as a "Product" on page 1 of the Agreement:

Maitake Combination Therapy for indications including but not limited to the following: breast cancer, brain tumor, hepatocellular

carcinoma, pancreatic cancer, renal cell carcinoma, nasopharyngeal carcinoma, prostate cancer, cervix cancer, oral/ pharynx/larynx

cancer, lung cancer, leukemia, myeloma, lymphoma, gastric cancer, thyroid cancer, esophageal cancer, gastric cancer, small intestine

cancer, large intestine/colon/rectal cancer, ovary cancer, skin cancer, head and neck, soft tissue sarcoma, bone tumor, bladder

cancer, and cholangiocarcinomab."

1.2 Paragraph 1.6 of the Agreement is hereby amended and restated in its entirety as follows:

.6 "Territory" shall mean:

1.3 Paragraph 2 of the Agreements is hereby amended and restated in its entirety as follows:

1.4 Paragraph 3 of the Agreement is hereby amended to add the following Paragraph 3.3 after Paragraph 3.2 and all of its sub-paragraphs:

For the avoidance of doubt, no additional milestone payments will be made with respect to the Product numbered 6."

1.5 Paragraph 4 of the Agreement is hereby amended and restated in its entirety to read as follows:

Royalty Charge: 5% of the net sales, provided, however, that if at any given time BioLite is obligated to pay its licensor amounts

in excess of 3% of such net sales, the Parties will adjust the Royalty Charge as mutually agreed between the Parties."

WITNESS WHEREOF the Parties hereto have caused this Addendum to be executed, in duplicate, each Party taking a copy,

as of the date first written above.